Abstract
The review provides a definition of the concept of «patient-reported outcomes (PRO)». The main components of PRO include health-related quality of life (QoL), symptoms assessed by the patient, functional status, satisfaction with treatment. The review presents a description of the most frequently used questionnaires for assessing QoL in patients with chronic kidney disease (CKD). It has been shown that the physical component of QoL decreases in predialysis stages of CKD. As CKD progresses, the Physical Component Summary (PCS) of the SF-36 questionnaire deteriorates, as well as the scale scores of Physical functioning, Pain, General health, and Role limitations caused by Physical problems (RP). Among the CKD-specific QoL scales, a deterioration in the scores of Symptoms/Problems, Burden of Kidney Disease, Effects of kidney disease on daily life is observed. There are no convincing data in the literature in favor of a decrease in psychosocial aspects of QoL in patients with CKD. The review presents the definition of «comprehensive conservative care» proposed by the experts convened at the 2013 KDIGO Controversies Conference on Supportive Care. It has been shown that comprehensive conservative care can be a fairly effective method of choice for elderly patients with Stage 5 CKD. It has been demonstrated that a decrease in PCS is independently associated with CKD progression and an increased risk of death. However, the information on QoL in predialysis CKD is insufficient. The use of different questionnaires for QoL assessment complicates data comparison. Randomized clinical trials are practically absent, which reduces the value of the results obtained.
Publisher
Non-profit organization Nephrology
Reference68 articles.
1. United States Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. United States Food and Drug Administration, Rockville, MD, 2009. Available from: https://www.fda.gov/media/77832/download
2. Halyard MY. The use of real-time patient-reported outcomes and quality-of-life data in oncology clinical practice. Expert Rev Pharmacoecon Outcomes Res 2011;11(5):561-570. doi: 10.1586/erp.11.62
3. Bottomley A, Pe M, Sloan J et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 2016;17(11):e510-e514. doi: 10.1016/S1470-2045(16)30510-1
4. Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res 2011;2(4):137-144. doi: 10.4103/2229-3485.86879
5. Schick-Makaroff K, Thummapol O, Thompson S et al. Strategies for incorporating patient-reported outcomes in the care of people with chronic kidney disease (PRO kidney): a protocol for a realist synthesis. Syst Rev 2019;8(1):20. doi: 10.1186/s13643018-0911-6